相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。O-0023 * CONCUR: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REGORAFENIB MONOTHERAPY IN ASIAN PATIENTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (MCRC)
J. Li et al.
ANNALS OF ONCOLOGY (2014)
O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)
V. Heinemann et al.
ANNALS OF ONCOLOGY (2014)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
John Primrose et al.
LANCET ONCOLOGY (2014)
O-0026 * FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP
C. Cremolini et al.
ANNALS OF ONCOLOGY (2013)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger et al.
LANCET ONCOLOGY (2013)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
Matthew T. Seymour et al.
LANCET ONCOLOGY (2013)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna et al.
LANCET ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus
Rene Adam et al.
ONCOLOGIST (2012)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial
Michel Ducreux et al.
LANCET ONCOLOGY (2011)
Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy
Alain Hendlisz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer
Sandra L. Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
B. Nordlinger et al.
ANNALS OF ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger et al.
LANCET (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk
Fairooz Kabbinavar et al.
ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
Miriam Koopman et al.
LANCET (2007)
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Matthew T. Seymour et al.
LANCET (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
Bernard Nordlinger et al.
EUROPEAN JOURNAL OF CANCER (2007)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2006)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
A Grothey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2004)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
分享论文
